Blood platelets and serum VEGF in cancer patients

[1]  A. Palotie,et al.  Peripheral Blood Platelets Express VEGF-C and VEGF which Are Released during Platelet Activation , 1998, Thrombosis and Haemostasis.

[2]  H. Joensuu,et al.  High pre‐treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small‐cell lung cancer , 1998, International journal of cancer.

[3]  S. Ōmura,et al.  The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis. , 1998, British Journal of Cancer.

[4]  M. Melbye,et al.  High incidence of classical Kaposi's sarcoma in Iceland and the Faroe Islands. , 1998, British Journal of Cancer.

[5]  E. Ingham,et al.  Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. , 1998, British Journal of Cancer.

[6]  T. Nakano,et al.  Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma. , 1998, British Journal of Cancer.

[7]  H. Verheul,et al.  Platelet: transporter of vascular endothelial growth factor. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  J. El Benna,et al.  Intracellular pool of vascular endothelial growth factor in human neutrophils. , 1997, Blood.

[9]  H. Joensuu,et al.  A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. , 1997, Blood.

[10]  P. Vermeulen,et al.  Serum basic fibroblast growth factor and vascular endothelial growth factor in metastatic renal cell carcinoma treated with interferon alfa-2b. , 1997, Journal of the National Cancer Institute.

[11]  J. Weyler,et al.  EVALUATION OF TUMOUR ANGIOGENESIS AS A PROGNOSTIC MARKER IN MALIGNANT MESOTHELIOMA , 1997, The Journal of pathology.

[12]  S. Ōmura,et al.  Lactacystin, a specific inhibitor of the proteasome, inhibits human platelet lysosomal cathepsin A-like enzyme. , 1997, Biochemical and biophysical research communications.

[13]  K. Alitalo,et al.  Serum vascular endothelial growth factor is often elevated in disseminated cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  F. Parazzini,et al.  A phase I-II trial of fixed-dose carboplatin and escalating paclitaxel in advanced ovarian cancer. , 1997, European journal of cancer.

[15]  S. Rafii,et al.  Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[16]  P. Vermeulen,et al.  Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. , 1997, British Journal of Cancer.

[17]  Marty W. Mayo,et al.  TNF- and Cancer Therapy-Induced Apoptosis: Potentiation by Inhibition of NF-κB , 1996, Science.

[18]  G. Hubens,et al.  Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  A. Bousvaros,et al.  Elevation of serum interleukin-6 but not serum-soluble interleukin-2 receptor in children with Crohn's disease. , 1996, Journal of pediatric gastroenterology and nutrition.

[20]  J. Gołąb,et al.  Potentiation of the anti‐tumor effect of actinomycin D by tumor necrosis factor α in mice: Correlation between in vitro and in vivo results , 1996, International journal of cancer.

[21]  G. Neufeld,et al.  Interleukin 6 Induces the Expression of Vascular Endothelial Growth Factor (*) , 1996, The Journal of Biological Chemistry.

[22]  E. Partridge,et al.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer , 1996, The New England journal of medicine.

[23]  F. Parazzini,et al.  Survival of women with advanced ovarian cancer and complete pathologic response at second‐look laparotomy , 1996, Cancer.

[24]  Y. Satow,et al.  Expression of the Vascular Endothelial Growth Factor ( VEGF ) Receptor Gene , KDR , in Hematopoietic Cells and Inhibitory Effect of VEGF on Apoptotic Cell Death Caused by Ionizing Radiation , 2022 .

[25]  M. Piccart,et al.  Docetaxel in advanced ovarian cancer: preliminary results from three phase II trials. EORTC Early Clinical Trials Group and Clinical Screening Group, and the MD Anderson Cancer Center. , 1995, European journal of cancer.

[26]  S. Soker,et al.  Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. , 1995, Cancer research.

[27]  D. Pinsky,et al.  Induction of interleukin 6 (IL-6) by hypoxia in vascular cells. Central role of the binding site for nuclear factor-IL-6 , 1995, The Journal of Biological Chemistry.

[28]  J B Vermorken,et al.  European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J. Albina,et al.  Interleukin-6 activity in wounds. , 1994, The American journal of physiology.

[30]  F. Parazzini,et al.  Response to second-line weekly cisplatin chemotherapy in ovarian cancer previously treated with a cisplatin- or carboplatin-based regimen. , 1994, European journal of cancer.

[31]  J. Ziegler.  Endemic Kaposi's sarcoma in Africa and local volcanic soils , 1993, The Lancet.

[32]  J. Thigpen,et al.  Second‐line chemotherapy for recurrent carcinoma of the ovary , 1993, Cancer.

[33]  J. Neijt,et al.  Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer. , 1991, European journal of cancer.

[34]  G. Scarfone,et al.  Salvage chemotherapy for ovarian cancer recurrence: weekly cisplatin in combination with epirubicin or etoposide. , 1991, Gynecologic oncology.

[35]  S. Rubin,et al.  Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  T. Hirano,et al.  Interleukin-6 is a potent thrombopoietic factor in vivo in mice. , 1989, Blood.

[37]  M. Stuart,et al.  Hemostatic alterations in inflammatory bowel disease: response to therapy. , 1978, The American journal of digestive diseases.